P192 | PERSISTENT CYTOKINE RELEASE SYNDROME IN PATIENTS RECEIVING BISPECIFIC ANTIBODY THERAPY FOR MULTIPLE MYELOMA: A CASE SERIES

Bispecific antibodies such as Talquetamab have shown efficacy in relapsed/refractory multiple myeloma (RRMM), with cytokine release syndrome (CRS) being a common early toxicity. However, data on persistent or recurrent CRS during ongoing therapy are limited. We report three cases of RRMM patients tr...

Celý popis

Podrobná bibliografie

Hlavní autoři:	R. Della Pepa, A. Leone, F. Grimaldi, S. Avilia, M. Memoli, F. Pane.
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Ferrata Storti Foundation 2025-09-01
Edice:	Haematologica
On-line přístup:	https://haematologica.org/article/view/12389
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!